Detalhe da pesquisa
1.
Association of indicators of extensive disease and rifampin-resistant tuberculosis treatment outcomes: an individual participant data meta-analysis.
Thorax
; 79(2): 169-178, 2024 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38135489
2.
Optima TB: A tool to help optimally allocate tuberculosis spending.
PLoS Comput Biol
; 17(9): e1009255, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34570767
3.
Effectiveness and safety of delamanid- or bedaquiline-containing regimens among children and adolescents with multidrug resistant or extensively drug resistant tuberculosis: A nationwide study from Belarus, 2015-19.
Monaldi Arch Chest Dis
; 91(1)2021 Jan 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33470080
4.
Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe.
Clin Microbiol Infect
; 2024 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38490355
5.
Tuberculosis Co-Infection Is Common in Patients Requiring Hospitalization for COVID-19 in Belarus: Mixed-Methods Study.
Int J Environ Res Public Health
; 19(7)2022 04 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35410048
6.
Tuberculosis Drug Susceptibility, Treatment, and Outcomes for Belarusian HIV-Positive Patients with Tuberculosis: Results from a National and International Laboratory.
Tuberc Res Treat
; 2021: 6646239, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33868727